Equities

LTR Pharma Ltd

LTR Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)1.22
  • Today's Change-0.01 / -0.82%
  • Shares traded285.37k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction (ED). Its lead product SPONTAN is set apart from existing ED therapies by its mechanism of action-intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less. SPONTAN (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction. The Company's subsidiary is LTR Pharma Inc.

  • Revenue in AUD (TTM)49.00k
  • Net income in AUD-6.95m
  • Incorporated2020
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tryptamine Therapeutics Ltd-100.00bn-100.00bn55.19m----9.12----------0.0049----------------------------0.0342--------------
Anteotech Ltd514.89k-8.88m58.27m40.00--9.38--113.18-0.0039-0.00390.00020.00210.0699--2.55---120.47-75.24-159.35-84.74-----1,724.74-1,444.66----0.3055--26.8527.9329.82--68.39--
Neurotech International Ltd3.34m-5.07m69.32m----5.73--20.78-0.0054-0.00540.00370.01170.38070.0011.59---57.86-134.56-63.92-163.66100.00---151.98-462.3838.81--0.00--165.9867.3934.94------
Actinogen Medical Ltd291.02k-13.04m73.98m----3.31--254.22-0.0061-0.00610.00010.00720.0159--0.0433---71.44-48.56-78.20-51.97-----4,482.26-5,188.44---163.100.0159---20.637.31-21.32------
Percheron Therapeutics Ltd615.48k-11.92m76.72m8.00--7.13--124.65-0.0135-0.01350.00070.01040.045--0.2912---87.09-75.92-122.82-89.91-----1,936.57-4,028.81---1,956.650.0042--59.9056.21-4.74------
Proteomics International LaboratoriesLtd1.41m-6.38m87.77m----9.32--62.27-0.0507-0.05070.01120.07190.1346--6.45---61.88-60.46-67.65-69.49-----459.82-290.18---208.630.0331---4.24-1.45-3.23--60.39--
Argenica Therapeutics Ltd192.09k-5.48m92.87m----6.43--483.46-0.0518-0.05180.00190.11280.0148--0.7326---42.28---50.70-------2,852.56-----21,829.870.00--214.90---13.80------
Paradigm Biopharmaceuticals Ltd6.52m-58.65m94.49m----3.97--14.49-0.1875-0.18750.01860.0680.138--1.10---124.19-52.89-150.28-58.0699.86---899.60-543.63---961.470.006---23.2214.97-12.99------
LTR Pharma Ltd49.00k-6.95m103.87m----58.08--2,119.73-0.0499-0.04990.00040.0211---------------------14,192.84-----414.020.00-------378.00------
Data as of Nov 22 2024. Currency figures normalised to LTR Pharma Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.